Program
capivasertib
Also written as “Capivasertib”, “AZD5363” and “Intermittent dosing of AZD5363”.
Its studies are mostly in Breast Neoplasms · Prostatic Neoplasms · Triple Negative Breast Neoplasms · Hematologic Neoplasms, led by AstraZeneca.
Drug pageCapivasertib: every studyAll 55 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 239 open or running | phase 3since May 20, 2019 | Oct 21, 2010 | Nov 1, 2027phase 3 · NCT04862663 |
Also a collaborator on its studies: Apices Soluciones S.L., Parexel and Quotient Sciences.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 9 earlier studies, Oct 21, 2010 to Feb 20, 2020.
- Jun 9, 2017Named capivasertibINNProposed as its International Nonproprietary Name in WHO's List 117 · before, AZD5363
- Jul 9, 2020Phase 3 study in Prostatic NeoplasmsNCT04493853 · 1,012 enrolled · United States, Argentina, Australia and more
- Dec 15, 2020Phase 1 study in Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)NCT04712396 · 11 enrolled · Germany
- Jan 15, 2021Phase 1 study in Advanced Solid TumoursNCT04742036 · 16 enrolled · China
- Mar 17, 2021Phase 3 study in Locally Advanced (Inoperable) or Metastatic Breast CancerNCT04862663 · 893 enrolled · United States, Argentina, Australia and more
- Jun 28, 2021Phase 1 study in Hematologic NeoplasmsNCT04944771 · 48 enrolled · Germany
- Jul 1, 2021Phase 1 study in Solid TumourNCT04958226 · 21 enrolled · United States
- Jul 19, 2021Phase 2 study in RecurrenceNCT05008055 · 30 enrolled · United States, Canada, Denmark and more
- Mar 18, 2022Phase 3 study in Prostatic NeoplasmsNCT05348577 · 1,035 enrolled · United States, Australia, Belgium and more
- Apr 11, 2022Phase 1 study in Healthy VolunteerNCT05419401 · 7 enrolled · United Kingdom
- Sep 9, 2024Phase 3 study in Breast NeoplasmsNCT06635447 · 293 enrolled · China
- Nov 28, 2024Phase 3 study in Breast NeoplasmsNCT06764186 · 101 enrolled · Spain
- Jul 17, 2025Phase 1 study in Healthy ParticipantsNCT07088913 · 20 enrolled · United States
- Nov 17, 2025Phase 1 study in Healthy ParticipantsNCT07241065 · 42 enrolled · Germany
- Jan 7, 2026Phase 1 study in Moderate Hepatic ImpairmentNCT07343960 · 20 planned · United States
Ahead
- Nov 11, 2026Primary completion: phase 1 study in Moderate Hepatic ImpairmentNCT07343960
- Nov 1, 2027Primary completion: phase 3 study in Locally Advanced (Inoperable) or Metastatic Breast CancerNCT04862663
- Nov 30, 2027Primary completion: phase 3 study in Breast NeoplasmsNCT06764186
TargetBeta
“Serine/threonine-protein kinase AKT inhibitor”ChEMBL 37, by rule
Studies
All 23 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07343960Moderate Hepatic Impairment · United States | 1 | Recruiting | Nov 11, 2026 | 20 |
| NCT07241065Healthy Participants · Germany | 1 | Completed | Jul 20, 2026 | 42 |
| NCT07088913Healthy Participants · United States | 1 | Completed | Feb 20, 2026 | 20 |
| NCT06764186Breast Neoplasms · Spain | 3 | Active, not recruiting | Nov 30, 2027 | 101 |
| NCT06635447Breast Neoplasms · China | 3 | Active, not recruiting | Oct 31, 2026 | 293 |
| NCT05419401Healthy Volunteer · United Kingdom | 1 | Completed | Jul 12, 2022 | 7 |
| NCT05348577Prostatic Neoplasms · United States, Australia, Belgium and more | 3 | Active, not recruiting | Mar 4, 2026 | 1,035 |
| NCT05008055Recurrence · United States, Canada, Denmark and more | 2 | Completed | Aug 22, 2023 | 30 |
| NCT04958226Solid Tumour · United States | 1 | Completed | Feb 6, 2023 | 21 |
| NCT04944771Hematologic Neoplasms · Germany | 1 | Completed | May 4, 2022 | 48 |
| NCT04862663Locally Advanced (Inoperable) or Metastatic Breast Cancer · United States, Argentina, Australia and more | 3 | Active, not recruiting | Nov 1, 2027 | 893 |
| NCT04742036Advanced Solid Tumours · China | 1 | Completed | Jul 29, 2022 | 16 |
| NCT04712396Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer) · Germany | 1 | Completed | Mar 25, 2021 | 11 |
| NCT04493853Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Oct 7, 2024 | 1,012 |
| NCT04305496Locally Advanced (Inoperable) or Metastatic Breast Cancer · United States, Argentina, Australia and more | 3 | Active, not recruiting | May 9, 2023 | 818 |
| NCT04087174Prostatic Neoplasms · United States, Spain | 1 | Completed | Jun 22, 2021 | 27 |
| NCT03997123Triple Negative Breast Neoplasms · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Mar 16, 2026 | 923 |
| NCT03742102Triple Negative Breast Neoplasms · United States, Canada, Poland and more | 2 | Active, not recruiting | Nov 29, 2024 | 243 |
| NCT01895946Advanced Solid Malignancy, · Netherlands, United Kingdom | 1 | Completed | Feb 2015 | 33 |
| NCT01692262Prostatic Neoplasms · United States, United Kingdom | 1 | Completed | Jun 2014 | 59 |
| NCT01625286Breast Neoplasms · Bulgaria, Canada, Czechia and more | 2 | Completed | Jan 28, 2017 | 148 |
| NCT01353781Advanced Solid Malignancy · Japan | 1 | Completed | Jul 2014 | 39 |
| NCT01226316Breast Neoplasms · United States, Canada, Denmark and more | 1 | Completed | Apr 26, 2019 | 285 |
How it is read
Names in the registry
- “Capivasertib”, 16 entries
- “AZD5363”, 7 entries
- “Intermittent dosing of AZD5363”, 3 entries
- “AZD5363 when combined with weekly paclitaxel.”, 2 entries
- “capivasertib”, 1 entry
Codes read as this program: AZD5363.
Conditions, from the studies’ own filings
- Breast Neoplasms, 7 studies
- Prostatic Neoplasms, 4 studies
- Triple Negative Breast Neoplasms, 2 studies
- Hematologic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.